José Valentín López

Headed to #USCAP2026 for a couple of days of great science, insightful discussions, and connecting with future colleagues in pathology! See you all there! @TheUSCAP #PathX

Analysis of B7-H3 in >150,000 cancer samples from >50 histologies. A new therapeutic target is born. Congrats to Carly Miller on her first-author paper. Thanks also to @CarisLife for their collaboration. aacrjournals.org/cancerrescommu…

Great discussions happening at the 2024 GRS and GRC on Lipidomics!

Its out! Check out our latest review article “Androgen receptor and estrogen receptor variants in prostate and breast cancers” in the Journal of Steroid Biochemistry and Molecular Biology 🧫 🧬 authors.elsevier.com/a/1izxk3QIyUNZ…

@UMNChemistry’s summer intramural softball was back after a Covid-hiatus! Congrats to The Dynamic Scatterers for taking 3rd place! 🙌🏽✨💪🏽 @TLOkeefe12 @RealMMA10 @W_AlvarezReyes @Finetraces786 @caseyh2os + lots of friends!

Wonderful presentation by @AlbigesL @GustaveRoussy arguing for doublet v triplet tx. Slides updated to reflect data from @brian_rini @VUMCDiscoveries & @DrTHut @TheUSONetwork presented at #ASCO23 just yesterday (wow!). Come join us in Room E451!

Thx to 🌟@OncMedEdCoP team for creating a home for anyone interested in #OncMedEd. ✨All✨ are welcome regardless of profession, training, specialty, or @ASCO membership. Special thx to @JenSchwartzIUSM and @doctormb1 for our #ASCO23 events! Join us: surveymonkey.com/r/ASCOMedEdCoP

Thank you again @ConquerCancerFd for the Annual Meeting Research Award! #ASCO23 #ConquerCancer

#ASCO23 Day 4: Prioritizing and Sequencing Therapy for Advanced Prostate Cancer

Thanks for sharing such an important point! There are so many side-effects that are not seeing! #LCSM #ASCO23

PROSPECT:Can we omit RT in selected patients? ☢️Preoperative Chemotherapy with Selective Chemoradiation versus Chemoradiation for Locally Advanced Rectal Cancer: ☢️Yes! There are no differences regarding DFS, OS, pCR, and locoregional reoccurrence! @asco @oncoalert #ASCO23

#ASCO23 Plenary session underway with results of the PROSPECT trial 🎗️Compared neoadjuvant CRT vs FOLFOX 🎗️ Non-inferiority DFS was met 🎗️Path CR and QOL similar 🎗️Neoadjuvant FOLFOX, with selective use CRT, is an effective tx for pts with CT2N+, cT3N-, or cT3N+ rectal cancer

Its time for the #ASCO23 Plenary Session!

Very interesting session on Patient-Centric Clinical Trial Design in GU Cancers happening now at #ASCO23

It’s time for the 2023 Medical Student & Resident Abstract Forum. Come check out my poster (22) in S103. #ASCO23 @LatinxOncology

“PSMA PET will become the new gold standard for imaging of prostate cancer” GU Poster discussion session @ASCO #ASCO23

ASCO 23 GU cancer highlight @ChrisSweens1 @brian_rini CONTACT-3, THOR, PEACE1, 5 yr KN426 and much more. anchor.fm/the-uromigos/e…

Getting ready for #ASCO23 day 2 with a 10K run by Lake Michigan.

It does! @ConquerCancerFd @ASCO #ASCO23